IMVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immunovant Inc (IMVT) is not a good buy for a beginner, long-term investor at this time. The recent failure of its Phase 3 trials for Batoclimab has caused significant negative sentiment, and the stock has experienced notable declines in price. While hedge funds are increasing their positions, the lack of positive catalysts, weak financial performance, and mixed analyst ratings make this stock a high-risk investment currently.
The MACD is slightly positive at 0.0819, indicating a weak bullish signal, but RSI at 49.1 is neutral, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point of 24.328, with resistance at 25.503 and support at 23.153. Overall, technical indicators do not suggest a strong entry point.
Hedge funds are increasing their positions, with a 133.13% rise in buying activity over the last quarter. Analysts see potential in the Graves' disease program and other ongoing trials.
The failure of Phase 3 trials for Batoclimab in Thyroid Eye Disease has caused a sharp decline in stock price and negative sentiment. Analysts have lowered price targets, and there is no significant news flow expected in the near term for key programs.
In Q3 2026, the company reported no revenue growth (0% YoY), a net income loss of -$110.6M (-0.44% YoY), and a significant EPS decline of -19.74% YoY. These figures indicate weak financial performance.
Analyst ratings are mixed. Some analysts maintain a Buy or Outperform rating, citing potential in Graves' disease and other programs, but others have downgraded or maintained a Hold rating due to the lack of near-term catalysts and recent trial failures. Price targets range from $22 to $50, with a median target of $28.
